Document is current
Any future updates will be listed below
-
Authors
El Ghalbouni, A.
Snijders, T. J.
Amerein, A.
Tolboom, N.
Patt, M.
Maurer, C. J.
van der Schaaf, I. C.
Lapa, C.
Braat, A. J. A. T. https://orcid.org/0000-0002-8824-8697
-
Funding
Funding for this research was provided by:
KWF Dutch Cancer Society
- License Information
-
More Information
Article History
Received: 25 August 2025
Accepted: 18 September 2025
First Online: 15 October 2025
Declarations
:
: Informed consent was waived by both institutional ethics committees, because of the retrospective nature of this study. This study was conducted in line with the principles of the Declaration of Helsinki and all applicable local regulations.
: N. Tolboom is consultant for Telix Pharmaceuticals and Theranova and receives in kind research support from Curium Pharmaceuticals. C. Lapa reports prior consulting activities for Blue Earth Diagnostics Ltd. & Novartis. A.J.A.T. Braat is consultant for Boston Scientific, Terumo, GE Healthcare & Telix Pharmaceuticals, receives research support from Boston Scientific, Telix Pharmaceuticals, Ariceum Therapeutics & Siemens Healthineers. All others authors have no relevant financial or non-financial interests to disclose.
